Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Tours – page 9

539 clinical trials in Tours, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Tours at a glance
539
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

539 trials in Tours

Open in trial search

Myelodysplastic syndrome

Recruiting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Hormone-dependent prostate cancer

Recruiting

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Plasma cell myeloma

Recruiting

Study Comparing Elranatamab and Lenalidomide with Daratumumab and Lenalidomide for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Psychotic disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) in patients with psychosis associated with Alzheimer's disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Chronic coronary syndrome

Recruiting

Study on the Safety and Effectiveness of Short Dual Antiplatelet Therapy with Ticagrelor, Clopidogrel, and Prasugrel in Patients Aged 65+ with Coronary Artery Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Clopidogrel
  • Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Asthma

Recruiting

Study on Stopping Dupilumab in Patients with Severe Asthma Who Have Been on the Drug for Over 3 Years

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Triple negative breast cancer

Recruiting

Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Unicancer

Non-small cell lung cancer stage III

Recruiting

Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Central nervous system lymphoma+1

Recruiting

Study of Epcoritamab, Lenalidomide, and Rituximab for Patients with Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Small cell lung cancer limited stage

Recruiting

Study on Toripalimab and Tifcemalimab for Patients with Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tifcemalimab
  • Sponsor:Shanghai Junshi Biosciences Co. Ltd.

Cirrhosis alcoholic

Recruiting

Study on Carvedilol for Preventing Complications in Patients with Early-Stage Cirrhosis and High Blood Pressure in the Liver

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carvedilol
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Tours

What the registry says about research in the country

01 Respiratory Research

Clinical trials focusing on pulmonary disorders include studies on idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, evaluating new therapeutic approaches to improve lung function and patient outcomes.

  • Idiopathic Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis
02 Oncology Studies

Groundbreaking research in cancer treatment encompasses multiple myeloma, leukemia, and esophageal cancer, with trials evaluating novel targeted therapies and immunotherapy approaches.

  • Multiple Myeloma
  • Acute Myeloid Leukemia
  • Colorectal Cancer
  • Pleural Mesothelioma
03 Immunology and Infectious Diseases

Research initiatives exploring immune system disorders and viral infections, including innovative vaccine development for COVID-19 and cytomegalovirus, plus studies on immunosuppression management.

  • COVID-19 Vaccines
  • Cytomegalovirus Prevention
  • Sustained Immunosuppression
04 Neurological Disorders

Studies addressing neurological conditions, focusing on multiple sclerosis treatment strategies and investigating therapies for ADHD and Alzheimer's-related psychosis.

  • Multiple Sclerosis
  • ADHD
  • Alzheimer's Disease Psychosis
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.